Skip to main content

ORIGINAL RESEARCH article

Front. Ophthalmol.
Sec. Inflammatory Eye Diseases
Volume 5 - 2025 | doi: 10.3389/fopht.2025.1491981
This article is part of the Research Topic Advancements in Non-Infectious Uveitis: Emerging Therapies and Novel Drug Administration Route View all 3 articles

Secukinumab in refractory non-infectious anterior uveitis

Provisionally accepted
Otto Olivas-Vergara Otto Olivas-Vergara *Inés Hernanz Inés Hernanz Pablo E Borges-Deniz Pablo E Borges-Deniz Fredeswinda Isabel Romero-Bueno Fredeswinda Isabel Romero-Bueno Olga Sanchez Pernaute Olga Sanchez Pernaute Ester Carreño Ester Carreño
  • University Hospital Fundación Jiménez Díaz, Madrid, Spain

The final, formatted version of the article will be published soon.

    Background: Secukinumab is a monoclonal antibody that selectively neutralizes interleukin-17A and has shown efficacy in the treatment of psoriatic arthritis, psoriasis, and axial spondyloarthritis. Its use in non-anterior non-infectious uveitis is controversial, with evidence generally not supporting its effectiveness in these conditions. However, the role of secukinumab in anterior non-infectious uveitis remains unclear. Methods: Case series. Five patients with biological therapy-refractory non-infectious anterior uveitis who were treated with secukinumab were included. Results: All 5 patients experienced a uveitis flare-up during treatment, and secukinumab failed to induce long-term remission in 2 of these patients, who also had uncontrolled systemic disease. Conclusion: Secukinumab failed to prevent uveitis flare-up in these patients with biological therapy-refractory disease. Further studies are necessary to determine the potential role of secukinumab in the treatment of anterior uveitis.

    Keywords: secukinumab, Anterior uveitis, Uveitis, Spondyloarthritis, Psoriatc arthritis

    Received: 05 Sep 2024; Accepted: 06 Feb 2025.

    Copyright: © 2025 Olivas-Vergara, Hernanz, Borges-Deniz, Romero-Bueno, Sanchez Pernaute and Carreño. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Otto Olivas-Vergara, University Hospital Fundación Jiménez Díaz, Madrid, Spain

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.